Repurposed Drug: ESNtx005
Since its establishment, ESN has progressed into a precision therapeutics company, developing its first repurposed drug, ESNtx005. This drug is targeted to specific rare disease subgroups within the type of Cardiomyopathy market segment.
ESNtx005 features include:
​
-
Repurposed Drug in Orphan Indications (de-risked)
-
Novel Composition of Matter (high value)
-
Specific Cardiomyopathy Segments – areas of major unmet medical need
-
Precision Medicine (accelerated clinical development pathway)
ESNtx005 repurposed drug significantly reduces development cost, time and risks towards commercialisation.
Click Image To Enlarge
Orphan Drugs Market
With the US government's initiatives for rare disease patients, orphan drugs have become a significant segment of the therapeutic drug landscape.
​
-
The US government’s 1983 Orphan Drug Act provides substantial incentives to pharmaceutical companies to develop orphan drugs.
-
Between 2017-21, 118 orphan drugs (48.8% of 242 new drugs in the market) were approved by the FDA.
-
Orphan drugs are at CAGR 12%, projected to reach US$300b in sales, reaching 20% of all drug sales by 2028.
-
US Government’s Medicare and Medicaid programs provide the majority of the orphan drug costs to patients.
-
In 2021, Medicare and Medicaid collectively spent US$92b (>30% of all drugs) on orphan drugs